Developing science,
delivering therapies

4d

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach
developing-science

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do
delivering-therapies

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

4D pharma CEO, Duncan Peyton, and CSO, Alex Stevenson, will participate in a fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on Thursday, April 22, 2021 at 1:00 p.m. BST (8:00 a.m. ET).
This announcement is intended to guide holders of Ordinary Shares, which are admitted to trading on AIM, through the process of exchanging Ordinary Shares for ADSs tradeable on Nasdaq, and to answer certain related frequently asked questions applicable to holders of the Ordinary Shares.
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.

BACK TO TOP